Asafoetida and indigestion
What 2 graded rows on asafoetida agree on for indigestion, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Asafoetida page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Asafoetida page, with its PubMed record.
Your question
Asafoetida and indigestion
2 rows · 105 peopleThey agree: both rows found an improvement.
- CGrade C× 2
- Rows
- 2
- Trials
- 2
- People
- 105
What the rows share
From the rowsThe best-graded row, grade C, is a randomized trial of 62 people (2025) and found an improvement.
The rows run from 43 to 62 people, published from 2018 to 2025: 2 single studies.
The rows
2 improved- CGrade CFunctional dyspepsia symptoms (early satiety, bloating, heartburn) · Improved
RCT · n 62 · 2025 · Adults with functional dyspepsia symptoms
250 mg/day · 14 days
Significant time, treatment and treatment × time effects for early satiety, bloating and heartburn (P < .05), with more responders by day 14. Stool form improved, reaction time fell 44% and Bergen Insomnia Scale scores improved (both P < .001).
- CGrade CFunctional dyspepsia symptoms and quality of life · Improved
RCT · n 43 · 2018 · People with moderate to severe functional (non-ulcer) dyspepsia in India
250 mg twice daily (500 mg/day) · 30 days
About 81% of the asafoetida group improved significantly in overall score and quality of life versus placebo (p < 0.01), and 66% were symptom-free at the end. Symptom scores improved in both groups but more with asafoetida (−5.67 to −25.29 vs −1.55 to −6.0; p ≤ 0.001). No adverse events or blood-test changes occurred.